Revolutionizing Anti-HER2 Therapies for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer: Current Advancements and Future Perspectives
Biliary tract cancers (BTCs) encompass a heterogeneous group of rare tumors, including intrahepatic cholangiocarcinoma (iCCA), extrahepatic cholangiocarcinoma (eCCA), gallbladder cancer (GBC) and ampullary cancer (AC). The present first-line palliative treatment regimen comprises gemcitabine and cisplatin in combination with immunotherapy based on two randomized controlled studies. Despite the thorough investigation of these palliative treatments, long-term survival remains low.Moving beyond conventional chemotherapies and immunotherapies, the realm of precision medicine has demonstrated remarkable efficacy in malignancies such as breast and gastric cancers, characterized by notable HER2 overexpression rates.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Britte HEA ten Haaft, Manuel Pedregal, Javier Prato, Heinz-Josef Kl ümpen, Victor Moreno, Angela Lamarca Tags: Review Source Type: research
More News: Bile Duct Cancer | Cancer | Cancer & Oncology | Cholangiocarcinoma | Gallbladder Cancer | Gastric (Stomach) Cancer | Gastroenterology | HER2 | Immunotherapy | Palliative | Study